Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Pulmatrix, Inc.PULM · Entity 8249 | Chief Scientific Officer | June 05, 2018 | June 06, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Pulmatrix, Inc.
Report date June 05, 2018 · Filed June 06, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.47 · Expires 2028-06-05 | Direct | 795,000 |
Reported balance
After 2018-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-05 · Grant · Acquired 795,000 · Balance 795,000 F1: The option vested as to 25% on June 5, 2018 and the remaining 75% vests in thirty-six (36) equal monthly installments with 2.083% vesting on the last day of each of the next thirty-six (36) months that follow June 5, 2018, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vested as to 25% on June 5, 2018 and the remaining 75% vests in thirty-six (36) equal monthly installments with 2.083% vesting on the last day of each of the next thirty-six (36) months that follow June 5, 2018, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2018 Filed Jun 6, 2018 18:01 UTC | Pulmatrix, Inc. PULM · Entity 8249 | GrantStock Option (Right to Buy) · Derivative | 795,000 | $0.00 Strike: $0.47 | $0.00 |
DisclosureSEC source: 0000899243-18-015299 · doc4.xml · derivative · entry 1 Hava David L. · CIK 0001645110 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 795,000 Underlying: Common Stock · 795,000 shares Expires 2028-06-05 F1 · derivative.exercise_date: The option vested as to 25% on June 5, 2018 and the remaining 75% vests in thirty-six (36) equal monthly installments with 2.083% vesting on the last day of each of the next thirty-six (36) months that follow June 5, 2018, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. Read SEC document |
| March 22, 2017 Filed Mar 22, 2017 18:49 UTC | Pulmatrix, Inc. PULM · Entity 8249 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,263 | $0.00 Strike: $2.21 | $0.00 |
DisclosureSEC source: 0000899243-17-008411 · doc4.xml · derivative · entry 3 Hava David L. · CIK 0001645110 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,292 Underlying: Common Stock · 2,263 shares Expires 2020-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: On March 22, 2017, the Reporting Person acquired 2,263 shares of common stock upon a partial exercise of this option. Following the exercise, the Reporting Person may acquire an additional 1,292 shares of common stock pursuant to this option. F2 · derivative.exercise_date: The option, representing the right to purchase a total of 3,555 shares of common stock, was fully vested and exercisable as of February 10, 2014. F3 · derivative.underlying_shares: On March 22, 2017, the Reporting Person acquired 2,263 shares of common stock upon a partial exercise of this option. Following the exercise, the Reporting Person may acquire an additional 1,292 shares of common stock pursuant to this option. F3 · balance_after: On March 22, 2017, the Reporting Person acquired 2,263 shares of common stock upon a partial exercise of this option. Following the exercise, the Reporting Person may acquire an additional 1,292 shares of common stock pursuant to this option. Read SEC document |
| March 22, 2017 Filed Mar 22, 2017 18:49 UTC | Pulmatrix, Inc. PULM · Entity 8249 | Exercise / conversionCommon Stock | 2,263 | $2.21 | $5,001.23 |
DisclosureSEC source: 0000899243-17-008411 · doc4.xml · nonDerivative · entry 1 Hava David L. · CIK 0001645110 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,263 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 20, 2017 Filed Mar 22, 2017 18:49 UTC | Pulmatrix, Inc. PULM · Entity 8249 | GrantStock Option (Right to Buy) · Derivative | 75,100 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0000899243-17-008411 · doc4.xml · derivative · entry 2 Hava David L. · CIK 0001645110 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,100 Underlying: Common Stock · 75,100 shares Expires 2027-03-20 F1 · derivative.exercise_date: The option vests as to 25% on March 20, 2018 and the remaining 75% vests in thirty-six (36) equal monthly installments with 2.083% vesting for each of the next thirty-six (36) months that follow March 20, 2018, subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.